Ticar Related Published Studies
Well-designed clinical trials related to Ticar (Ticarcillin)
Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. [2007.09]
Well-designed clinical trials possibly related to Ticar (Ticarcillin)
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
A protocol for a multicentre randomised controlled trial of continuous
beta-lactam infusion compared with intermittent beta-lactam dosing in critically
ill patients with severe sepsis: the BLING II study. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
Other research related to Ticar (Ticarcillin)
A prospective study of cefepime versus ticarcilline/clavulanate as empirical
treatment of febrile neutropenia in lymphoma patients. [2011]
High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. [2010.07]
Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. [2005.06]
Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. [2005.03]
Other possibly related research studies
Acinetobacter baumanii folliculitis in a patient with AIDS. [2005.05]
[Treatment of bronchial superinfections: data related to stability of antibiotics in portable pumps] [2006.03]
An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. [2006.08]
Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. [2006.05]
Stenotrophomonas maltophilia bacteremia in burn patients. [2006.03]
Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci. [2005.12]
Ceftriaxone prophylaxis in abdominal, cardiovascular, thoracic, orthopaedic, neurosurgical and general surgery: a review of practice 1996 - 2003. [2005.09]
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. [2005.12]
Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. [2005.10.15]
Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. [2005.11]
Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae. [2005.07]
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. [2005.10]
Effect of systematic empiric treatment with imipenem on the bacterial ecology in a burns unit. [2005.11]
Natural antimicrobial susceptibility patterns of Kluyvera ascorbata and Kluyvera cryocrescens strains and review of the clinical efficacy of antimicrobial agents used for the treatment of Kluyvera infections. [2005.04]
[Nosocomial Stenotrophomonas maltophilia infections in a university hospital] [2005.01]
Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. [2005.03]
Variability of laboratory identification and antibiotic susceptibility reporting of Pseudomonas spp. isolates from dogs with chronic otitis externa. [2007.04]
Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. [2006.10]
Outpatient intravenous antibiotics for methicillin-resistant Staphylococcus aureus sinusitis. [2007.03]
Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. [2007.06.15]
[Prescribing fortified eye drops] [2007.04]
Use of 27 parenteral antimicrobial agents in north of France hospitals. [2007.02]
Alcaligenes xylosoxidans conjunctivitis. [2007.08]
Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. [2007.05]
Ertapenem for complicated intra-abdominal infections: a meta-analysis of randomized controlled trials. [2008.02.09]
Treatment of anaerobic infection. [2007.12]
[Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination] [2007.12]
Multidrug-resistant Ewingella americana: a case report and review of the literature. [2007.12]
Antimicrobial therapy for Stenotrophomonas maltophilia infections. [2007.04]
Antibiotic susceptibility and mechanisms of beta-lactam resistance among clinical strains of Pseudomonas aeruginosa: first report in Algeria. [2008.04]
[Etiology of urinary tract infections and antimicrobial susceptibility of urinary pathogens] [2007.11]
Meta-analysis: ertapenem for complicated intra-abdominal infections. [2008.05]
Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. [2008.01]
Antiinfective agents affecting cognition: a review. [2007.12]
Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis. [2008.05]
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. [2008.11]
Rapid adaptation of antibiotic therapy for community-acquired peritonitis using direct cultures on antibiotic agar plates: pilot study. [2009.08]
Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. [2009.07]
Stenotrophomonas maltophilia endogenous endophthalmitis: clinical presentation, sensitivity spectrum and management. [2009.06]
The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. [2009.04]
A bullous lesion in a neutropenic adolescent. [2009.02]
In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection. [2009.05]
Detection and quantification of drug-specific T cells in penicillin allergy. [2009.04]
Temocillin revived. [2009.02]
[Aerobic bacteria associated with acute appendicitis in children] [2009.01]
Antimicrobial delivery by intrasynovial catheterisation with systemic administration for equine synovial trauma and sepsis. [2010.04]
[Infectious keratitis and cosmetic lenses: a five-case retrospective study] [2010.04]
Three decades of beta-lactamase inhibitors. [2010.01]
[Predictive factors of acquisition of epidemic extended-spectrum beta-lactamase-producing Escherichia coli] [2010.02]
[Stability: a factor to consider in antibiotic-lock solutions] [2010.02]
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. [2011.04]
Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. [2011.03]
In vitro antimicrobial activity of calcium sulfate and hydroxyapatite (Cerament Bone Void Filler) discs using heat-sensitive and non-heat-sensitive antibiotics against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. [2011.03]
Airway microbial culture and susceptibility patterns in dogs and cats with respiratory disease of varying severity. [2010.12]
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. [2010.12]
Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. [2010.08]
|